Disruption of hepatic insulin signalling induces NAFLD and hepatic insulin resistance through insulin receptor substrate-2 gene deletion, leading to upregulation of SREBP-1, leading to the development of obesity, diabetes and NAFLD in laboratory animals (9). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.